1. A method of treating at least one Non-metabolic disorder in a patient comprising the step of administering to a patient suffering from said Non-metabolic disorder, a therapeutically effective amount of dopamine agonist with central action, wherein said dopamine agonist with central action is effective to treat said at least one Non-metabolic disorder in said patient, wherein said Non-metabolic disorder is selected from the group consisting of vascular diseases, proinflammatory TATUS vessels, procoagulant state, pro-oxidant state, or endothelial dysfunction and wherein said dopamine agonist is administered in such a way as to induce a dopamine agonist peak plasma level of between 4:00 and 12:00 hours dnya.2. A method according to Claim. 1, wherein said patient also suffers from pre-diabetic state, metabolic syndrome or type 2 diabetes, and said method of treatment is also aimed at Pre-Diabetes, metabolic syndrome and / or diabetes type 2.3. A method according to Claim. 1 wherein the dopamine agonist is selected from central action of D2 dopamine receptor agonists and / or dofamina.4 D1 receptor agonists. A method according to claim. 3, wherein said dopamine agonist is a compound related compound sporyni.5. A method according to claim. 4, wherein said compound, ergot related compounds, has a low activity of the agonist serotonin 2B receptor, or lacks eyu.6. A method according to claim. 4, wherein said compound, ergot related compounds, selected from the group consisting of bromocriptine, lisuride, dihydroergotoxin, dihydro-alpha-ergocryptine, terguride and with1. Способ лечения по меньшей мере одного неметаболического нарушения у больного, включающий стадию введения больному, страдающему указанным неметаболическим нарушением, терапевтически эффективного количества агониста дофамина с центральным действием, причем указанный агонист дофамина с центральным действием эффективен для лечения указанного по меньшей мере одного неметаболического нарушения у указанного больн
